Oncology Brothers: Practice-Changing Cancer Discussions

299 Episodes

Reverse

Management of Uncommon EGFR Mutations in NSCLC: Dr. Susan Scott

2026-11-1417:32

In this episode of the Oncology Brothers podcast, we dived deep into the world of uncommon EGFR mutations in non-small cell lung cancer (NSCLC). Joined by Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins School of Medicine, as we explored the intricacies of EGFR exon 20 insertions, the third most common mutation, and other rare mutations such as G719X, S768I, and L861Q. Key topics discussed include: The importance of broad-based next-generation sequencing (NGS) testing for identifying EGFR mutations Current treatment options for exon 20 insertions, including the combination of amivantamab and chemotherapy, and the promising data surrounding sunvozertinib The challenges and considerations in treating patients with central nervous system (CNS) metastases and the role of systemic treatments versus localized therapies Insights into the sequencing of treatments for rare EGFR mutations and the potential of datopotamab deruxtecan (Dato-DXd) in refractory settings Join us for an informative discussion that sheds light on the evolving landscape of targeted therapies for EGFR-mutated NSCLC. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes! #EGFRmNSCLC, #Exon20Insertion, #G719X, #S768I, #L861Q, #OncologyBrothers

Durvalumab + Enfortumab vedotin FDA Approval for Muscle Invasive Bladder Cancer (MIBC): VOLGA

2026-11-1325:37

In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas from Fred Hutch Cancer Center to discuss the recent FDA approval of the durvalumab plus enfortumab vedotin (EV) regimen for cisplatin-ineligible muscle-invasive bladder cancer (MIBC), based on the findings from the VOLGA trial. Join us as we explored: The evolution of treatment standards for MIBC over the past 2 years Key insights from the VOLGA trial, including study design, findings, and clinical implications The significance of event-free survival (EFS) and overall survival (OS) rates in the context of this new regimen The balance between overtreatment and undertreatment in patient care The side effect profiles of durvalumab and enfortumab vedotin, and how they impact treatment decisions Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! #BladderCancer, #MIBC, #Durvalumab, #EnfortumabVedotin, #VOLGATrial

Management of NSCLC with Common EGFR Mutations: Dr. Ben Levy

2026-11-1320:44

We dived into this evolving landscape of treatment options for common sensitizing EGFR mutations in non-small cell lung cancer (NSCLC). In this episode, we were joined by Dr. Benjamin Levy, a thoracic medical oncologist at Johns Hopkins, to discuss the latest advances in frontline therapies, including single-agent osimertinib, osimertinib plus chemotherapy, and the promising combination of amivantamab and lazertinib. Key topics covered include: The prevalence of EGFR mutations in metastatic non-small cell adenocarcinoma The shift from single-agent osimertinib to combination therapies and the implications for patient care Factors influencing treatment decisions, including patient preference, side effect profiles, and co-mutations The importance of shared decision-making in oncology Insights into managing central nervous system (CNS) involvement and the nuances of treatment sequencing at progression Whether you're a healthcare professional or simply interested in the latest in cancer treatment, this episode provides valuable insights into the complexities of managing EGFR-mutated lung cancer. Don't miss out on this informative discussion! Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Stay tuned for our next episode featuring Susan Scott, MD, where we will explore uncommon EGFR mutations. #EGFRmNSCLC, #Osimertinib, #Amivantamab, #Lazertinib, #OncologyBrothers

ESMO 2026 Lung Cancer Highlights: DeLLphi-305, SAFFRON, KRASCENDO-1, PERSEE

2026-11-1127:43

Welcome back to the Oncology Brothers podcast! In this episode, we discussed practice changing/informing studies from the ESMO 2026 conference, focusing on the latest advancements in lung cancer treatment. Join us as we welcomed Dr. Hossein Borghaei, a thoracic medical oncologist from the Fox Chase Cancer Center, to discuss 4 key studies that could change clinical practice: DeLLphi-305: how the combination of durvalumab and tarlatamab after chemotherapy has led to a remarkable increase in median overall survival (OS) for patients with extensive-stage small cell lung cancer (ES-SCLC) SAFFRON: Learn about the efficacy of osimertinib combined with savolitinib for EGFR-mutated lung cancer patients with MET overexpression, showing significant improvements in progression-free survival (PFS) and OS compared with traditional chemotherapy KRASCENDO-1: We explored the new KRAS G12C inhibitor, divarasib, and its promising results against established treatments like sotorasib and adagrasib, highlighting its favorable toxicity profile PERSEE: Talked about the ongoing debate on whether chemotherapy should be added to immunotherapy for patients with high PD-L1 scores, as new data suggests potential benefits Tune in for an insightful discussion that aims to keep you informed on the latest in oncology and improve patient care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #LungCancer, #ESMO2026, #NSCLC, #SCLC, #OncologyBrothers

ESMO 2026 GI Cancer Highlights: HERIZON-GEA-01, CLARITY-GASTRIC01, AZUR1, CHECKMATE 8HW, HARMONi-GI1

2026-11-0923:45

Welcome to the Oncology Brothers podcast! In this episode, we dived into the highlights from the ESMO 2026 conference, focusing on key studies in gastrointestinal (GI) malignancies. Join us as we discussed: HERIZON-GEA-01: Zanidatamab, a biparatopic HER2 antibody for HER2-positive upper GI adenocarcinoma, showcasing updated overall survival (OS) data and its implications for treatment CLARITY-Gastric 01: The first antibody-drug conjugate (ADC) targeting CLDN18.2, demonstrating significant improvements in OS for patients in the second- and third-line settings AZUR-1: Dostarlimab’s recent approval for MSI-high rectal cancer, highlighting its potential to allow patients to avoid radiation and surgery CheckMate 8HW: Insights into the superiority of dual checkpoint inhibition over single-agent immunotherapy for MSI-high metastatic colorectal cancer HARMONi-GI1: A look at ivonescimab combined with chemotherapy in biliary tract cancer, showing promising results despite being a China-only study Tune in for expert insights from GI medical oncologists Drs. Eric Van Cutsem and Manish Shah, as they share their thoughts on these pivotal studies and their impact on clinical practice. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers podcast! #GIOncology, #ESMO2026, #UpperGI, #Colorectal, #OncologyBrothers

#box-pro-ellipsis-179468050140464{-webkit-line-clamp:2;}Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers: Practice-Changing Cancer Discussions